Results 221 to 230 of about 316,749 (274)

Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis.

Lancet, The, 2015
G. Siontis, G. Stefanini, D. Mavridis, Konstantinos C. Siontis, F. Alfonso, M. Pérez-Vizcayno, R. Byrne, A. Kastrati, B. Meier, G. Salanti, P. Jüni, S. Windecker   +11 more
semanticscholar   +3 more sources

Preventing treatment failures in coronary artery disease: what can we learn from the biology of in-stent restenosis, vein graft failure and internal thoracic arteries?

Cardiovascular Research, 2020
Coronary artery disease (CAD) remains one of the most important causes of morbidity and mortality worldwide, and the availability of percutaneous or surgical revascularization procedures significantly improves survival.
C. Spadaccio, C. Antoniades, A. Nenna, Calvin Chung, R. Will, M. Chello, M. Gaudino   +6 more
semanticscholar   +1 more source

Stenting for in-stent restenosis

Catheterization and Cardiovascular Interventions, 2000
Intravascular ultrasound studies have shown that additional stent implantation is the only percutaneous technique that allows for recovery of all the lumen area of the original implantation procedure. Despite this theoretical advantage, information on systematic additional stent implantation is still forthcoming, especially concerning the impact of new
D, Antoniucci, R, Valenti, G, Moschi, M, Trapani, G M, Santoro, L, Bolognese, E, Taddeucci, E, Dovellini   +7 more
openaire   +2 more sources

Restenosis after aortic stenting

Cardiology in the Young, 2004
Aortic coarctation is a recognized arteriopathy in patients with Williams’ syndrome. We present an adolescent with Williams’ syndrome who developed rapid restenosis after primary stenting of coarctation of the aorta. We believe such restenosis within the stent is due to a proliferative response of the abnormal aortic wall.
Joydeep, Mookerjee, Derek, Roebuck, Graham, Derrick   +2 more
openaire   +2 more sources

Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon.

JACC: Cardiovascular Interventions, 2019
OBJECTIVES The aim of this randomized controlled trial was to investigate a novel sirolimus-coated balloon (SCB) compared with the best investigated paclitaxel-coated balloon (PCB).
R. Ali, M. A. S. Abdul Kader, Wan Azman Wan Ahmad, T. Ong, H. Liew, A. Omar, A. S. Mahmood Zuhdi, A. A. Nuruddin, B. Schnorr, B. Scheller   +9 more
semanticscholar   +1 more source

Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial.

Journal of the American Medical Association (JAMA)
Importance Drug-coated balloons offer a potentially beneficial treatment strategy for the management of coronary in-stent restenosis. However, none have been previously evaluated or approved for use in coronary circulation in the United States ...
Robert W. Yeh, R. Shlofmitz, Jeffrey Moses, William B. Bachinsky, S. Dohad, Steven G. Rudick, R. Stoler, Brian K Jefferson, William Nicholson, John D. Altman, Cinthia T. Bateman, Amar Krishnaswamy, J. Grantham, Frank J. Zidar, S. Marso, J. Tremmel, Cindy Grines, Mustafa I. Ahmed, A. Latib, Behnam N. Tehrani, J. Abbott, Wayne B. Batchelor, Paul Underwood, D. Allocco, Ajay J. Kirtane, R. Shlofmitz, Jeffrey Moses, William B. Bachinsky, S. Dohad, Steven G. Rudick, R. Stoler, Brian K Jefferson, William Nicholson, John D. Altman, Robert W. Yeh, Cinthia T. Bateman, Amar Krishnaswamy, J. Grantham, Frank J. Zidar, Rajendran Sabapathy, J. Tremmel, Cindy Grines, Mustafa I. Ahmed, A. Latib, Behnam N. Tehrani, K. Alaswad, Carey Kimmelstiel, William Dixon, Arthur Reitman, Lawrence Ang, Justin Levisay, J. Abbott, Kathleen Kearney, F. Jaffer, Saroj Neupane, Kevin Croce, K. Shunk, Angela Taylor, Matthew Saybolt, Claro F Diaz, Alpesh Shah, K. Lotun, Johannes Brechtken, Himanshu Agarwal, R. Patel   +64 more
semanticscholar   +1 more source

Intracoronary Stent Restenosis

2021
Despite contemporary drug-eluting stent (DES) technology, intracoronary stent restenosis (ISR) occurs in up to 10% of patients, increasing with intervention of complex lesions. The presentation of ISR is still challenging for optimal treatment [1].
Keisuke Yasumura, Annapoorna Kini, Samin K. Sharma   +2 more
openaire   +1 more source

Treatment of coronary in-stent restenosis: a systematic review

Journal of Geriatric Cardiology, 2018
Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (
L. Pleva, P. Kukla, O. Hlinomaz
semanticscholar   +1 more source

Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States.

Journal of the American College of Cardiology, 2020
BACKGROUND There is a paucity of data on the burden of in-stent restenosis (ISR) in the United States as well as on its presentation and appropriate treatment strategies.
I. Moussa, D. Mohananey, J. Saucedo, G. Stone, R. Yeh, K. Kennedy, R. Waksman, P. Teirstein, J. Moses, C. Simonton   +9 more
semanticscholar   +1 more source

In-stent Restenosis of drug-eluting Stents

Future Cardiology, 2013
Drug-eluting stents (DES) have emerged as an improved alternative to bare-metal stents by demonstrating reduced rates of restenosis and target lesion revascularization. This emergence has led to the unrestricted use of DES for various indications and lesions, and subsequently revealed DES in-stent restenosis as a novel interventional therapeutic ...
Sa'ar, Minha, Augusto D, Pichard, Ron, Waksman   +2 more
openaire   +2 more sources